1. Home
  2. RNAZ vs GRDX Comparison

RNAZ vs GRDX Comparison

Compare RNAZ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

27.9M

Sector

Health Care

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.22

Market Cap

33.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAZ
GRDX
Founded
2016
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
33.2M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
RNAZ
GRDX
Price
$1.04
$3.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.2K
★ 147.2K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$1.87
52 Week High
$12.60
$6.93

Technical Indicators

Market Signals
Indicator
RNAZ
GRDX
Relative Strength Index (RSI) 25.80 36.24
Support Level N/A $3.23
Resistance Level $1.93 $4.19
Average True Range (ATR) 0.16 0.79
MACD -0.02 -0.26
Stochastic Oscillator 6.42 26.36

Price Performance

Historical Comparison
RNAZ
GRDX

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: